Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-κB-mediated COX-2 expression and apoptosis

Free Radic Biol Med. 2014 Aug:73:260-9. doi: 10.1016/j.freeradbiomed.2014.05.009. Epub 2014 May 22.

Abstract

Inflammatory reactions and oxidative stress are implicated in the pathogenesis of focal segmental glomerulosclerosis (FSGS), a common chronic kidney disease with relatively poor prognosis and unsatisfactory treatment regimens. Previously, we showed that osthole, a coumarin compound isolated from the seeds of Cnidium monnieri, can inhibit reactive oxygen species generation, NF-κB activation, and cyclooxygenase-2 expression in lipopolysaccharide-activated macrophages. In this study, we further evaluated its renoprotective effect in a mouse model of accelerated FSGS (acFSGS), featuring early development of proteinuria, followed by impaired renal function, glomerular epithelial cell hyperplasia lesions (a sensitive sign that precedes the development of glomerular sclerosis), periglomerular inflammation, and glomerular hyalinosis/sclerosis. The results show that osthole significantly prevented the development of the acFSGS model in the treated group of mice. The mechanisms involved in the renoprotective effects of osthole on the acFSGS model were mainly a result of an activated Nrf2-mediated antioxidant pathway in the early stage (proteinuria and ischemic collapse of the glomeruli) of acFSGS, followed by a decrease in: (1) NF-κB activation and COX-2 expression as well as PGE2 production, (2) podocyte injury, and (3) apoptosis. Our data support that targeting the Nrf2 antioxidant pathway may justify osthole being established as a candidate renoprotective compound for FSGS.

Keywords: Accelerated focal segmental glomerulosclerosis; Glomerular epithelial hyperplasia lesions; Glomerular hyalinosis/sclerosis; Nrf2 pathway; Osthole; Periglomerular inflammation; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Animals
  • Antioxidants / metabolism
  • Apoptosis / drug effects*
  • Calcium Channel Blockers / pharmacology*
  • Cnidium / metabolism
  • Coumarins / pharmacology*
  • Cyclooxygenase 2 / biosynthesis
  • Dinoprostone / biosynthesis
  • Disease Models, Animal
  • Female
  • Glomerulosclerosis, Focal Segmental / drug therapy*
  • Glomerulosclerosis, Focal Segmental / prevention & control
  • Glutathione Peroxidase / metabolism
  • Heme Oxygenase-1 / biosynthesis
  • Inflammation / drug therapy
  • Macrophage Activation / drug effects
  • Macrophages / immunology
  • Membrane Proteins / biosynthesis
  • Mice
  • Mice, Inbred BALB C
  • NF-E2-Related Factor 2 / metabolism*
  • NF-kappa B / antagonists & inhibitors
  • Oxidative Stress / drug effects
  • Plant Preparations / pharmacology
  • Podocytes / drug effects
  • Podocytes / pathology
  • Proteinuria / drug therapy
  • Proteinuria / prevention & control
  • Reactive Oxygen Species / metabolism

Substances

  • Antioxidants
  • Calcium Channel Blockers
  • Coumarins
  • Membrane Proteins
  • NF-E2-Related Factor 2
  • NF-kappa B
  • Nfe2l2 protein, mouse
  • Plant Preparations
  • Reactive Oxygen Species
  • Glutathione Peroxidase
  • Heme Oxygenase-1
  • Hmox1 protein, mouse
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Dinoprostone
  • osthol